Following its acquisition of Amylin Pharmaceuticals last year, Bristol-Myers Squibb is closing the latter’s headquarters in San Diego.
The US major says that by the end of next year, all work being done in San Diego will be switched to other B-MS sites. Some 420 people are employed at the Amylin HQ in commercial, R&D, manufacturing, corporate staff and administrative roles and 100-125 will be offered a transfer to B-MS facilities and the 300 other jobs will go. Some 150 staff had already left Amylin earlier this year.
Some 400 Amylin sales staff and 300 employees at a manufacturing site in West Chester, Ohio, will be integrated into B-MS, which paid about $5.30 billion to buy the diabetes specialist. AstraZeneca, which already had a major diabetes partnership with B-MS, then paid $3.40 billion for 50% of the profits from Amylin’s Byetta (exenatide) and its once-weekly successor Bydureon.
